comparemela.com

Latest Breaking News On - தொற்று நோய்கள் நிறுவனம் - Page 2 : comparemela.com

2021 2nd Quarterly PEPFAR Uganda Science Summit | Highlights on HIV, TB and COVID-19

Highlights on HIV, TB and COVID-19 Friday June 11, 2021, 9AM- noon (virtual) Summit Objectives:  To disseminate recent and ongoing HIV- and TB-related research from Uganda (whether PEPFAR-funded or non-PEPFAR funded) To highlight key findings on COVID-19 and its impact on HIV- and TB- related programs in Uganda    To inform national policies, programs and disease response activities Participants: US government PEPFAR team and implementing partners, Uganda Ministry of Health (including Public Health Fellowship Program and others), and other Ugandan health researchers. The Summit featured four sessions led by a set of session co-chairs from PEPFAR Uganda and from key stakeholders including Ministry of Health, Makerere University School of Public Health and others.  Each session consisted of a set of multiple five-minute presentations grouped by topic and given by scientists whose submitted presentations were accepted by the organizing committee.  Each session began with in

Opinion | Uganda Flattened the Curve Now We re Running Out of Time

July 9, 2021 By Mohammed Lamorde Dr. Lamorde is an expert on the management of infectious diseases in developing countries. He is the head of the global health security program at the Infectious Diseases Institute at Makerere University in Kampala, Uganda. Early in the pandemic, Uganda bought itself precious time at great economic cost to protect its people from Covid-19. There were lockdowns, international travel was restricted, and border screenings were introduced to prevent entry of the coronavirus. Cases of Covid-19 identified at borders or in communities were isolated, and people who had been in contact with those infected were quarantined and checked on by public health authorities.

剑桥大学研究显示:近半80岁以上老人辉瑞新冠mRNA疫苗两剂后才有效

剑桥大学研究显示:近半80岁以上老人辉瑞新冠mRNA疫苗两剂后才有效 眼下,疫苗仍是消除新冠全球大流行的主要希望。老年人群体、尤其是80岁以上人群该如何接种疫苗?接种后免疫效果如何?针对这些问题公开披露的证据甚少,推动疫苗开发的临床试验也很少招募80岁以上的志愿者。 北京时间6月30日晚间,顶级学术期刊《自然》(Nature)以“加快评审文章”(Accelerated Article Preview)形式在线发表的一项研究称,约半数80岁以上人群在打了第二针辉瑞-BioNTech的mRNA新冠疫苗(BNT162b2)后,才能实现最优的病毒中和作用。该项研究由英国剑桥大学、伦敦大学学院、格拉斯哥大学等团队联合完成,研究结果对于全球疫苗接种计划具有重要意义。在这项研究中,剑桥大学病毒学及临床微生物学教授、剑桥治疗免疫学和传染病学研究所核心研究人员Ravindra Gupta�

Seize the game-changing potential of mRNA vaccines

Seize the game-changing potential of mRNA vaccines
ghtcoalition.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ghtcoalition.org Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.